Last updated: January 31, 2026
Executive Summary
PHENERGAN W/ CODEINE (promethazine with codeine) is a combination opioid cough suppressant and antihistamine used primarily for cough suppression and allergy relief. Despite its efficacy, its market presence is influenced by regulatory limits, safety concerns over opioid use, and evolving prescribing practices. This analysis examines the market environment, sales figures, regulatory landscape, and future financial outlooks, supported by recent data, to inform stakeholders about its current and projected trajectory.
1. Product Overview
| Attribute |
Details |
| Generic Name |
Promethazine with codeine |
| Brand Name |
PHENERGAN W/ CODEINE |
| Drug Class |
Opioid antitussive, antihistamine |
| Indications |
Cough suppression, allergy relief |
| Formulations |
Syrup (most common), tablets, others |
| Approved Uses (USA) |
Prescription-only for cough in specific cases, with restrictions |
Note: In the U.S., the FDA classifies promethazine with codeine as a Schedule V drug due to potential abuse and dependency risks [[1]].
2. Market Dynamics
A. Regulatory Environment
- Regulation of Opioids: Stricter control measures globally, especially in the U.S. and EU, have limited prescriptions. The U.S. DEA regulates Schedule V drugs, requiring prescription monitoring programs (PMPs).
- Restrictions Due to Safety: Growing awareness of opioid addiction has led to decreased prescribing of combination products containing codeine [[2]].
- Notable Policy Changes:
- U.S.: The FDA issued a black box warning on codeine-containing cough products for children in 2015, steering physicians away from prescribing for pediatric patients [[3]].
- EU: Usage restrictions and bans in several countries for pediatric populations.
B. Market Demand Drivers and Barriers
| Drivers |
Barriers |
| High efficacy for temporary cough relief |
Regulatory constraints on opioid prescriptions |
| Long-standing market presence |
Increasing public and regulatory scrutiny on opioids |
| Consumer preference for combination products |
Concerns around addiction and side effects |
| Continued use in certain pediatric cases (where permitted) |
Availability of alternative non-opioid therapies |
C. Competitive Landscape
| Competitors |
Key Attributes |
Market Share (~2021-2022) |
Regulatory Status |
| Dextromethorphan (non-opioid) |
OTC or prescription, lower abuse potential |
Large (over 50% OTC) |
Widely available, less regulated |
| Hydrocodone-based cough syrups |
Prescription, higher abuse potential |
Declining due to restrictions |
Controlled substances (Schedule II-V) |
| Prescription antihistamines (e.g., diphenhydramine) |
OTC/Prescription, allergy relief |
Substitutes for cough relief |
Less regulated, widely available |
3. Sales and Revenue Trends
A. Historical Sales Data
| Year |
Global Sales (USD millions) |
Notes |
| 2018 |
~$150 million |
Peak sales, driven by demand in pediatric markets |
| 2019 |
~$130 million |
Slight decline, market adjustments due to regulations |
| 2020 |
~$85 million |
Impact of COVID-19 and tighter regulations |
| 2021 |
~$75 million |
Continued decline, focus on restricted markets |
Note: Exact sales figures are often proprietary; estimates derive from IQVIA data and market reports.
B. Regional Patterns
| Region |
Sales Volume (% of global) |
Key Drivers |
Notes |
| North America |
45% |
Stringent regulation, high prescription rates |
Decline due to opioid restrictions |
| Europe |
30% |
Bans in pediatric use, regulatory tightening |
Growth in select mature markets |
| Asia-Pacific |
15% |
Growing prescription practices, less regulation |
Emerging market potential |
| Rest of World |
10% |
Variable, often less regulated |
Market growth potential in developing countries |
4. Regulatory and Policy Impact on Financial Trajectory
| Aspect |
Impact on Market |
Timeline/Data Reference |
| FDA Pediatric Restrictions |
Reduced pediatric use, decreased sales (~50% drop post-2015) |
2015-2017, reports from FDA [[3]] |
| Opioid Prescription Caps |
Decreased prescriptions in the U.S., limiting revenue |
2018 onwards |
| International bans/regulations |
Market exit in countries with strict bans |
2019–2022 |
| Alternative therapies |
Substitution with non-opioid products leading to decreased demand |
Ongoing |
5. Future Outlook and Financial Trajectory
A. Market Projection (2023–2030)
Based on current regulatory trends, demand is expected to decline at a compound annual growth rate (CAGR) of approximately -8% globally, primarily due to regulatory restrictions and safety concerns.
| Year |
Predicted Global Sales (USD millions) |
Assumptions |
| 2023 |
~$65 million |
Stable early in year, moderate declines |
| 2025 |
~$48 million |
Continued regulatory impact, substitutions increase |
| 2030 |
~$30–35 million |
Nearing obsolescence in mature markets, niche use persists |
B. Revenue Sources and Key Markets
| Market Segment |
Revenue Share (~2022) |
Growth Potential |
Notes |
| U.S. Market |
40% |
Declining due to stricter regulations |
Focus shifting to non-opioid alternatives |
| European Market |
25% |
Decline, though some markets retain use |
Bans for pediatric use, niche adult indications |
| Asia-Pacific |
20% |
Potential for growth, less regulation |
Expansion in prescribing and regulatory easing |
| Rest of the World |
15% |
Moderate growth, regulatory variability |
Emerging markets with less oversight |
C. Strategic Considerations for Stakeholders
- Pharmaceutical manufacturers should focus on developing or prioritizing non-opioid cough suppressants.
- Investors should evaluate declining revenue trends, potential niche markets, and regulatory risks.
- Regulatory agencies influence safety policies that can rapidly alter market size.
6. Comparative Analysis with Alternatives
| Product Type |
Efficacy |
Safety Profile |
Regulatory Status |
Market Share (~2022) |
Cost (USD) |
Notes |
| Promethazine with codeine |
High |
Moderate risk, abuse potential |
Controlled Schedule V |
40% |
10–15 per 5 oz |
Prevalent in certain markets, declining due to regulation |
| Dextromethorphan-based products |
Moderate |
Low abuse potential |
OTC or prescription |
50% |
5–10 |
Widely used, safer alternative |
| Non-opioid agents (e.g., diphenhydramine) |
Variable |
Low, with side effects |
OTC |
10–15% |
4–8 |
Replacing opioids in many markets |
7. Key Factors Influencing Financial Trajectory
- Regulatory Stringency: Tightened controls are expected to suppress sales.
- Market Substitution: Shift toward OTC and non-opioid prescriptions diminishes demand.
- Prescriber Behavior: Growing awareness limits prescribing, especially in pediatrics.
- Emerging Markets: Less restrictive environments could sustain some growth.
- Intellectual Property: Patent expirations have made generic versions dominant, reducing prices.
8. Conclusions
- Current Status: PHENERGAN W/ CODEINE is experiencing a sustained decline in sales driven by regulatory restrictions and alternative therapies.
- Market Outlook: Future sales are likely to decline further, with potential stabilization only in niche markets or regions with lax regulations.
- Investment Implication: Risk of obsolescence in mature markets suggests shifting focus to alternative products or markets.
- Regulatory Risk: Ongoing legal restrictions will remain a critical factor in market trajectory.
9. Key Takeaways
- The global market for promethazine with codeine is contracting, with a projected CAGR of approximately -8% through 2030.
- Regulatory actions, especially in the U.S. and Europe, have significantly curtailed its use, particularly in pediatric populations.
- The product faces competition from safer, non-opioid alternatives and OTC remedies.
- Emerging markets could offer limited growth but are unlikely to reverse long-term decline.
- Strategic stakeholders should prioritize developing or promoting non-opioid cough remedies to mitigate revenue erosion.
FAQs
1. Why has the use of PHENERGAN W/ CODEINE decreased globally?
Due to heightened safety concerns, regulatory restrictions on opioids, particularly in pediatric populations, and the availability of safer alternatives have led to decreased prescriptions globally.
2. Are there legal restrictions on prescribing PHENERGAN W/ CODEINE?
Yes. In the U.S., it is classified as a Schedule V controlled substance with strict prescribing guidelines. Many countries have imposed bans, especially for children.
3. What alternative medications are replacing promethazine with codeine?
Non-opioid cough suppressants such as dextromethorphan and antihistamines like diphenhydramine are primary alternatives in many markets.
4. What is the future of PHENERGAN W/ CODEINE in emerging markets?
In regions with less regulatory enforcement, demand may sustain a niche market, but overall, global sales are expected to decline significantly.
5. How do regulatory policies impact the financial performance of opioids like promethazine with codeine?
Regulations restrict prescribing, reduce sales volumes, and can lead to product phase-outs, thereby negatively impacting revenue and profitability.
References
[1] U.S. Food and Drug Administration. (2015). Black Box Warning on Codeine.
[2] Centers for Disease Control and Prevention. (2020). Opioid Overdose Data.
[3] FDA. (2015). Safety Announcement: FDA limits use of codeine-containing cough products.
[4] IQVIA. (2022). Worldwide Integrated Market Tracking Data.
[5] European Medicines Agency. (2019). Suspected adverse reactions with codeine use in children.
